- 1.
Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic
cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa,
emicizumab, depends on its ability to bridge the antigens. Thromb
Haemost. 2017;117(7):1348-1357.
- 2.
Data on file. Genentech, Inc.
- 3.
Genentech. Therapeutic antibodies: the next generation.
https://www.gene.com/stories/therapeutic-antibodies-the-next-generation.
Accessed November 23, 2017.
- 4.
Sampei Z, Igawa T, Soeda T, et al. Identification and
multidimensional optimization of an asymmetric bispecific IgG antibody
mimicking the function of factor VIII cofactor activity. PLoS
One. 2013;8(2):e57479.
- 5.
Jayapal KP, Wlaschin KF, Hu WS, et al. Recombinant protein
therapeutics from CHO cells—20 years and counting. Chem Eng
Prog. 2007;10(suppl):40-47.
- 6.
Eloctate [package insert]. Waltham, MA: Bioverativ; 2017.
- 7.
Advate [package insert]. Westlake Village, CA: Baxalta; 2016.
- 8.
Afstyla [package insert]. Marburg, Germany: CSL Behring; 2017.
- 9.
Nuwiq [package insert]. Sweden: Octapharma; 2017.
- 10.
Kovaltry [package insert]. Whippany, NJ: Bayer HealthCare; 2016.
- 11.
Adynovate [package insert]. Westlake Village, CA: Baxalta; 2017.
- 12.
Novoeight [package insert]. Bagsvaerd, Denmark:Novo Nordisk; 2018.
- 13.
Jivi [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018.
- 14.
Mahlangu JN, Oldenburg J, Paz-Preil I, et al. Emicizumab prophylaxis
in hemophilia A with inhibitors. N Engl J Med. 2018;379(9):811-822.
- 15.
Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in
hemophilia A with inhibitors. N Engl J Med.
2017;377(9):809-818, Protocol.
- 16.
National Hemophilia Foundation. MASAC update on the approval and
availability of the new treatment: emicizumab (Hemlibra), for persons
with hemophilia A with inhibitors to factor VIII: interim guidance on
acute bleed management and use of laboratory assays. 2017;1-4.
- 17.
Kruse-Jarres R, Callaghan MU, Croteau SE, et al. Surgical experience
in two multicenter, open-label phase 3 studies of emicizumab in
persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2)
[abstract]. Presented at: ASH 59th Annual Meeting of the American
Society of Hematology; December 9-12, 2017; Atlanta, GA.